On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards for China and Best Practices were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on recent research and analysis of the global hemoglobin oxygen carrier technology market, as well as studies and evaluations of related companies in the industry, Frost & Sullivan has awarded Biorx Biotechnology Co., Ltd. (hereinafter referred to as 'Biorx') the '2025 Frost & Sullivan Global Hemoglobin Oxygen Carrier Technology Innovation Leadership Award'. Hazmi Yusof, Senior Vice President and Malaysia Regional Head at Frost & Sullivan, and Professor Wang Yu, President of the China Liver Disease Foundation, an expert consultant to the Frost & Sullivan Global Expert Advisory Group, and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented the award to Biorx Biotechnology Co., Ltd. on behalf of the company.
Bail's Biotechnology Co., Ltd.
"2025 Global Hemoglobin Oxygen Carrier Technology Innovation Leadership Award"
Hazmi Yusof, Senior Vice President and Malaysia Head of Frost & Sullivan, and Professor Wang Yu, Chairman of the China Hepatitis Prevention and Control Foundation, an expert consultant to the Frost & Sullivan Global Expert Advisory Group, and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented awards on behalf of Biorb Biotechnology Co., Ltd.
Bail's Bio is a global innovator in hemoglobin oxygen carriers, reshaping the paradigm of hypoxic therapy with the concept 'Oxygen is Medicine'.
Bail's Biotechnology Co., Ltd. (BIOS) was established in Hong Kong in 2024. It has successively achieved full acquisition of the proprietary technologies and intellectual property rights of New Xingjian and Xin Yikang in Hong Kong, as well as the acquisition of Runfang (Beijing). The integration of three major hemoglobin projects enables it to encompass human and veterinary drug certificates, patents, and core technologies globally in one go, making it the industry's only platform-level company covering the research, development, production, and commercialization of oxygen carriers for all species. The core product is Oxapex.®YQ23®OP-101 and others have formed a tiered structure: Oxapex®Approved for veterinary use in New Zealand, the EU, and the UK one after another, YQ23®The company has completed Phase I trials in the UK and initiated clinical trials for CLI and advanced solid tumors in Phase Ib/IIa in Hong Kong, China. OP-101 is currently undergoing multi-center organ preservation solution validation in Mainland China. The company recently completed a $40 million overseas financing with a post-investment valuation of $900 million, setting the highest single financing amount globally for the hemoglobin oxygen carrier market.
With the closed-loop technology of 'chemical modification-polymerization regulation-oxygen partial pressure targeted release', BIOS enables the safe and precise oxygen delivery of chemically stable hemoglobin in plasma. It can penetrate microthrombi and local ischemic areas where red blood cells cannot reach, providing an immediate and accessible new oxygen therapy solution for ischemia-reperfusion injury, acute anemia, and protection of ex vivo organs.
Deeply involved in the hypoxic medical scenario, we have established a new benchmark of "oxygen therapy + devices" driven by both innovation and practical application.
In clinical applications, BAILS Biotechnology focuses on four major scenarios: 'emergency oxygenation, perioperative organ protection, tumor sensitization, and chronic disease ischemia'. It constructs three major drug delivery pathways: intravenous injection, extracorporeal circulation, and off-site perfusion, forming a drug-device combination solution. Oxapex®Approved for use in New Zealand, the EU, and the UK as an adjunctive therapy for canine hemorrhagic shock, it can rapidly increase blood oxygen saturation within 15 minutes, providing a unique indexable hemoglobin drug for veterinary emergency care; YQ23®After Phase I safety verification of healthy volunteers, two Phase Ib/IIa trials for severe limb ischemia and advanced solid tumors are being conducted simultaneously in Hong Kong, China. A NDA submission schedule has been established. OP-101, as an additive to cardioplegic perfusion fluid, has completed myocardial protection verification at the animal level, capable of significantly reducing ischemia-reperfusion injury marker cTnI by more than 60%.
The company has established a high-barrier, replicable industrialization platform through the entire GMP system of 'Bovine Blood Collection - Viral Inactivation - Molecular Modification - Terminal Filling'. The single-batch production capacity can reach 100,000 units, supporting global clinical and commercial supply.
The modular pipeline platform supports diversified expansion and continuous layout in global regulatory markets.
Bail's Bio, based on the 'hemoglobin oxygen carrier+' modular technology platform, possesses highly flexible configuration capabilities and the advantage of rapid conversion to multiple national regulations. Its core lies in the plug-and-play combination of three modules: polymer molecular weight tailoring, oxygen affinity regulation, and immunogenicity removal, enabling rapid adaptation for different species, indications, and administration routes; the product has a leading standardization level, allowing for the switching of human and veterinary specifications on the same production line, supporting large-scale industrial scale-up.
The R&D - Production - Registration three major functional modules form a self-reinforcing ecosystem through a closed-loop architecture, endowing the pipeline with continuous iteration and global declaration capabilities. In the future, it will continue to expand into strategic emerging fields such as acute stroke, COVID-19 respiratory failure, organ extracorporeal preservation, and tumor radiosensitization. It aims to help global customers break through the boundaries of hypoxic therapy, reshape the paradigms of emergency and chronic disease management, and become the key drivers and best partners leading the upgrade of the oxygen medicine industry.
About the Frost & Sullivan Global Technology Innovation Leadership Award
The Frost & Sullivan Global Technology Innovation Leadership Award recognizes outstanding performance and achievements in technology innovation, market potential, customer service, brand, and other aspects by companies. The Frost & Sullivan team nominates a competitive group of excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. An independent judging panel composed of third-party investment and financing experts, financial specialists, bankers, and renowned listed entrepreneurs conducts a rigorous review of the enterprises nominated by the Frost & Sullivan team and decides to award the '2025 Global Hemoglobin Oxygen Carrier Technology Innovation Leadership Award' to Bayers Pharmaceuticals Technology Co., Ltd.
